Aclarion, Inc. Announces Adjournment of Special Meeting of Stockholders
Aclarion (NASDAQ: ACON), a healthcare technology company specializing in MRS and AI for back and neck pain treatment optimization, has announced the adjournment of its Special Meeting of Stockholders originally scheduled for February 28, 2025.
The meeting has been rescheduled to March 5, 2025, at 9:30 a.m. Mountain Time at the company's Broomfield, Colorado office. The adjournment aims to solicit additional votes for proposals outlined in the company's proxy statement filed with the SEC on February 3, 2025.
The record date remains January 6, 2025. Previously submitted proxies will remain valid unless revoked. Shareholders can modify their votes until 11:59 p.m. Mountain Time on March 4, 2025, either through Internet voting or by submitting a new signed proxy.
Aclarion (NASDAQ: ACON), un'azienda tecnologica nel settore sanitario specializzata in MRS e intelligenza artificiale per l'ottimizzazione del trattamento del dolore alla schiena e al collo, ha annunciato il rinvio della sua Assemblea Straordinaria degli Azionisti originariamente prevista per il 28 febbraio 2025.
L'assemblea è stata riprogrammata per il 5 marzo 2025, alle 9:30 ora di montagna presso l'ufficio dell'azienda a Broomfield, Colorado. Il rinvio ha l'obiettivo di raccogliere ulteriori voti per le proposte delineate nella dichiarazione di delega dell'azienda depositata presso la SEC il 3 febbraio 2025.
La data di registrazione rimane il 6 gennaio 2025. Le deleghe precedentemente inviate rimarranno valide a meno che non vengano revocate. Gli azionisti possono modificare i loro voti fino alle 23:59 ora di montagna del 4 marzo 2025, sia tramite voto online che presentando una nuova delega firmata.
Aclarion (NASDAQ: ACON), una empresa de tecnología en salud especializada en MRS e IA para la optimización del tratamiento del dolor de espalda y cuello, ha anunciado la suspensión de su Junta Especial de Accionistas originalmente programada para el 28 de febrero de 2025.
La reunión ha sido reprogramada para el 5 de marzo de 2025, a las 9:30 a.m. hora de montaña en la oficina de la empresa en Broomfield, Colorado. La suspensión tiene como objetivo solicitar votos adicionales para las propuestas delineadas en la declaración de poder de la empresa presentada a la SEC el 3 de febrero de 2025.
La fecha de registro sigue siendo el 6 de enero de 2025. Los poderes previamente enviados seguirán siendo válidos a menos que sean revocados. Los accionistas pueden modificar sus votos hasta las 11:59 p.m. hora de montaña del 4 de marzo de 2025, ya sea a través de votación por Internet o presentando un nuevo poder firmado.
Aclarion (NASDAQ: ACON)은 허리 및 목 통증 치료 최적화를 위한 MRS 및 AI 전문 헬스케어 기술 회사로, 원래 2025년 2월 28일로 예정된 주주 특별 회의를 연기한다고 발표했습니다.
회의는 2025년 3월 5일 오전 9시 30분 산악 표준시에 콜로라도주 브룸필드에 있는 회사 사무실에서 다시 개최됩니다. 이번 연기의 목적은 2025년 2월 3일 SEC에 제출된 회사의 위임장에 명시된 제안에 대한 추가 투표를 요청하기 위함입니다.
기록일은 2025년 1월 6일로 유지됩니다. 이전에 제출된 위임장은 철회되지 않는 한 유효합니다. 주주들은 2025년 3월 4일 오후 11시 59분 산악 표준시까지 인터넷 투표 또는 새로 서명된 위임장을 제출하여 투표를 수정할 수 있습니다.
Aclarion (NASDAQ: ACON), une entreprise de technologie de la santé spécialisée dans la MRS et l'IA pour l'optimisation du traitement de la douleur au dos et au cou, a annoncé le report de sa Réunion Spéciale des Actionnaires initialement prévue pour le 28 février 2025.
La réunion a été reprogrammée pour le 5 mars 2025 à 9h30, heure des montagnes, dans les bureaux de l'entreprise à Broomfield, Colorado. Le report vise à solliciter des votes supplémentaires pour les propositions décrites dans la déclaration de procuration de l'entreprise déposée auprès de la SEC le 3 février 2025.
La date d'enregistrement reste le 6 janvier 2025. Les procurations précédemment soumises resteront valides, sauf révocation. Les actionnaires peuvent modifier leurs votes jusqu'à 23h59, heure des montagnes, le 4 mars 2025, soit par vote en ligne, soit en soumettant une nouvelle procuration signée.
Aclarion (NASDAQ: ACON), ein Unternehmen für Gesundheitstechnologie, das sich auf MRS und KI zur Optimierung der Behandlung von Rücken- und Nackenschmerzen spezialisiert hat, hat die Verschiebung seiner ursprünglich für den 28. Februar 2025 geplanten außerordentlichen Hauptversammlung der Aktionäre bekannt gegeben.
Die Versammlung wurde auf den 5. März 2025 um 9:30 Uhr Mountain Time in der Unternehmenszentrale in Broomfield, Colorado, neu angesetzt. Die Verschiebung zielt darauf ab, zusätzliche Stimmen für die im Proxydokument des Unternehmens, das am 3. Februar 2025 bei der SEC eingereicht wurde, skizzierten Vorschläge zu sammeln.
Das Stichtagsdatum bleibt der 6. Januar 2025. Bereits eingereichte Vollmachten bleiben gültig, sofern sie nicht widerrufen werden. Aktionäre können ihre Stimmen bis 23:59 Uhr Mountain Time am 4. März 2025 ändern, entweder durch Internetabstimmung oder durch Einreichung einer neuen unterschriebenen Vollmacht.
- None.
- None.
Meeting adjourned to Wednesday, March 5, 2025 at 9:30 a.m. Mountain Time
BROOMFIELD, Colo., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ: ACON) (NASDAQ: ACONW), a healthcare technology company that leverages Magnetic Resonance Spectroscopy ("MRS"), artificial intelligence and a proprietary biomarker to optimize clinical treatments for low back and neck pain, today announced that its Special Meeting of Stockholders (the “Special Meeting”) scheduled for February 28, 2025 has been adjourned for the purpose of soliciting additional votes with respect to the proposals described in the Company’s definitive proxy statement for the Special Meeting, filed with the Securities and Exchange Commission (the “SEC”) on February 3, 2025.
The Special Meeting will be reconvened on Wednesday, March 5, 2025, at 9:30 a.m. Mountain Time, and will continue to be held at the Company’s corporate office at 8181 Arista Place, Suite 100, Broomfield, Colorado 80021.
The record date for determination of stockholders entitled to vote at the reconvened Special Meeting remains January 6, 2025. Stockholders as of January 6, 2025, the record date for the Special Meeting, are encouraged to vote as soon as possible.
Proxies previously submitted in respect of the Special Meeting will be voted at the adjourned Special Meeting unless properly revoked. Stockholders who have previously submitted their proxy or otherwise voted and who do not want to change their vote need not take any action. Stockholders can change their vote at any time before the Special Meeting by returning a signed proxy with a later date or transmitting a subsequent vote over the Internet by 11:59 p.m. Mountain Time on March 4, 2025.
Important Information
This material may be deemed to be solicitation material in respect of the Special Meeting to be reconvened and held on March 5, 2025. In connection with the Special Meeting, the Company filed a definitive proxy statement with the SEC on February 3, 2025. BEFORE MAKING ANY VOTING DECISIONS, STOCKHOLDERS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT, AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE SPECIAL MEETING. The proxy materials have been made available to shareholders who are entitled to vote at the Special Meeting. The Company’s proxy statement and any other materials filed by the Company with the SEC can be obtained free of charge at the SEC’s website at sec.gov or the Company’s website https://investors.aclarion.com/sec-filings.
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy ("MRS"), and a proprietary biomarker to optimize clinical treatments. Aclarion's technology addresses the
Forward-Looking Statements
Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" including statements about the Special Meeting. Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause the company's actual operating results to be materially different from any historical results or from any future results expressed or implied by such forward-looking statements. We have based these forward-looking statements on our current assumptions, expectations, and projections about future events. In addition to statements that explicitly describe these risks and uncertainties, readers are urged to consider statements that contain terms such as "will," "believes," "belief," "expects," "expect," "intends," "intend," "anticipate," "anticipates," "plans," "plan," to be uncertain and forward-looking. No information in this press release should be construed as any indication whatsoever of our future revenues, stock price, or results of operations. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the company's filings with the Securities and Exchange Commission including those discussed under the heading “Risk Factors” in our most recently filed reports on Forms 10-K and 10-Q.
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
646.823.8656
ksmith@pcgadvisory.com
FAQ
When is Aclarion's (ACON) rescheduled Special Meeting of Stockholders?
What is the record date for Aclarion's (ACON) Special Meeting?
Why did Aclarion (ACON) adjourn their Special Meeting of Stockholders?
Until when can ACON shareholders modify their votes for the Special Meeting?
